ClinicalTrials.gov record
Recruiting Phase 1 Interventional

TLN-372 in Advanced KRAS Mutant Solid Tumors

ClinicalTrials.gov ID: NCT07204340

Public ClinicalTrials.gov record NCT07204340. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 8, 2026, 3:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-Label, Multicenter, Phase 1 Trial to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of TLN-372 as a Single Agent and in Combination With Other Anti-Tumor Agents, in Patients With Advanced KRAS Mutant Solid Tumors

Study identification

NCT ID
NCT07204340
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 1
Lead sponsor
Treeline Biosciences, Inc.
Industry
Enrollment
240 participants

Conditions and interventions

Interventions

  • TLN-372 Drug
  • TLN-372 in combination with cetuximab Drug
  • TLN-372 in combination with pembrolizumab Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 28, 2025
Primary completion
Dec 2, 2031
Completion
Mar 31, 2032
Last update posted
Apr 20, 2026

2025 – 2032

United States locations

U.S. sites
6
U.S. states
6
U.S. cities
6
Facility City State ZIP Site status
University of Alabama at Birmingham Birmingham Alabama 35294 Recruiting
Dana-Farber Cancer Institute Boston Massachusetts 02215-5450 Recruiting
START Midwest Grand Rapids Michigan 49546 Recruiting
Washington University Medical Campus St Louis Missouri 63108 Recruiting
Memorial Sloan Kettering Cancer Center New York New York 10021-3402 Recruiting
Sarah Cannon Research Institute Nashville Tennessee 37203 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07204340, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 20, 2026 · Synced May 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07204340 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →